Galantamine for dementia in people with Down syndrome

Cochrane Database of Systematic Reviews

Volumn , Issue 1, 2009, Pages

  Mohan, Monica ^a   Bennett, Cathy ^b   Carpenter, Peter K ^c  

^a FRENCHAY HOSPITAL   (United Kingdom)

^b UNIVERSITY OF LEEDS   (United Kingdom)

^c Bath and North Somerset PCT ^*  (United Kingdom)

Author keywords

Alzheimer disease *drug therapy; etiology ; Cholinesterase inhibitors *therapeutic use ; Down syndrome *complications ; Galantamine *therapeutic use ; Humans

Indexed keywords

CHOLINESTERASE INHIBITOR; DONEPEZIL; GALANTAMINE; MEMANTINE; RIVASTIGMINE; PLACEBO; CARBAMIC ACID DERIVATIVE;

BEHAVIOR DISORDER; CINAHL; CLINICAL TRIAL; COGNITION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DATA BASE; DEMENTIA; DISEASE SEVERITY; DOWN SYNDROME; DRUG EFFICACY; DRUG SAFETY; EMBASE; HUMAN; MEDLINE; PSYCINFO; RANDOMIZED CONTROLLED TRIAL; REVIEW; SKILL; ALZHEIMER DISEASE; BIOSIS; OUTCOME ASSESSMENT; SYSTEMATIC REVIEW; TREATMENT OUTCOME; UNITED KINGDOM; UNSPECIFIED SIDE EFFECT; ECONOMIC ASPECT; HEART RATE; INFORMATION PROCESSING; METABOLISM; PATIENT MONITORING; POPULATION;

ALZHEIMER DISEASE; CHOLINESTERASE INHIBITORS; DOWN SYNDROME; HUMANS; PHENYLCARBAMATES;

EID: 62449151090     PISSN: 1469493X     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD007656     Document Type: Review

References (49)

1. Albert M, Cohen C. The test for severe impairment: an instrument for the assessment of patients with severe cognitive dysfunction. Jour- nal of the American Geriatric Society 1992;40:449-453
2. Alzheimer's Australia (in collaboration with the Down syndrome Association of Victoria). Down syndrome and Alzeimer's disease (available online at: http://www.alzheimers.org.au/upload/HS1.18.pdf; accessed November 2008). Vol. Sheet 1.18, Hawker, ACT: Alzheimer's Australia, 2005 (July).
3. American Association on Intellectual and Developmental Disabilities. Fact Sheet: AGING Older Adults and Their Aging Caregivers (available online: http://www.aaidd.org/Policies/faq-aging.shtml; accessed November 2008). Washington, DC: AAIDD, 2008 (6 August, date of last update).
4. Aylward EH, Burt DB, Thorpe LU, et al. Diagnosis of dementia in individuals with intellectual disability. Journal of Intellectual Disability Research 1997;41:152-164 (Pubitemid 27424986)
5. Ball SL, Holland AJ, Huppert FA, Treppner P, Watson P, Hon J. The modified CAMDEX informant interview is a valid and reliable tool for use in the diagnosis of dementia in adults with Down's syndrome. Journal of Intellectual Disability Research 2004;48(6):611-620 (Pubitemid 39214380)
6. Birks J. Cholinesterase inhibitors for Alzheimer's disease. Cochrane Database of Systematic Reviews 2006, Issue 1. Art. No.: CD005593. [DOI: 10.1002/14651858.CD005593]
7. Bishop J, Huether CA, Torfs C, Lorey F, Deddens J. Epidemiologic study of Down Syndrome in a racially diverse California population, 1989 - 1991. American Journal of Epidemiology 1997;145:134-147
8. Burt DB, Aylward EH. Test battery for the diagnosis of dementia in individuals with intellectual disability. Journal of Intellectual Disability Research 2000;44:175-180
9. Carpenter PK. Cardiovascular and autonomic function in Down syndrome - Prescribing implications. British Journal of Psychiatry 1995; 167:118b-119b.
10. Casanova M, Walker L, Whitehouse P, Price D. Abnormalities of the nucleus basalis of Meynert in Down Syndrome. Annals of Neurology 1985;18:310-313 (Pubitemid 15023103)
11. Cooke L, Mohan M. Difficulties in Conducting Research in Vulnerable Groups (Rapid Response to Hewison 2006, BMJ, also cited in this review). BMJ 2006 (16 August);E-publication:Available http: //www.bmj.com/cgi/eletters/333/ 7562/300#139733.
12. Cummings JL, Mega M, Gray K, et al. The Neuropsychiatric Inventory. Neurology 1994;44:2308-2314
13. Deb S, Hare M, Prior L. Symptoms of dementia among adults with Down's syndrome: a qualitative study. Journal of Intellectual Disability Research 2007;51:726-739 (Pubitemid 47249748)
14. Egger M, Davey Smith G, Schneider M, Minder C. Bias in metaanalysis detected by a simple, graphic test. BMJ 1997;315(7):629-634 (Pubitemid 27387172)
15. Evenhuis HM. Further evaluation of the Dementia Questionnaire for Persons with Mental Retardation (DMR). Journal of Intellectual Disability Research 1996;40:369-373
16. Evenhuis HM, Kengen MMF, Eurlings HAL. Dementia Questionnaire for People with Intellectual Disabilities (DLD). Sydney: Pearson Psychocorp, 2006.
17. Fan WT. Psychiatry of learning disability - a time to sow, a time to grow. Hong Kong Journal of Psychiatry 2001;11(1):1-3.
18. Folstein MF, Foltein SE, McHugh PR. "Mini-mental state" A practical method for grading the cognitive state of patients for the clinicians. Journal of Psychiatric Research 1975;12:185-198
19. Fraser B. Psychopharmacology and people with learning disability. Advances in Psychiatric Treatment 1999;5:471-477
20. Gedye A. Dementia Scale for Down's Syndrome. Manual. Vancouver, BC: Gedye Research and Consulting, 1995.
21. Greenwood RD, Nadas AS. The clinical course of cardiac disease in Down's syndrome. Pediatrics 1976;58:893.
22. Hewison J, Haines A. Overcoming barriers to recruitment in health research. BMJ 2006;333:300-302
23. Higgins JPT, Thompson SG. Quantifying heterogeneity in a metaanalysis. Statistics in Medicine 2002;21:1539-1558
24. Holland A J, Hon J, Huppert FA, et al. Population-based study of the prevalence and presentation of dementia in adults with Down's syndrome. British Journal of Psychiatry 1998;172:493-498 (Pubitemid 28247481)
25. Holland A J, Hon J, Huppert A, et al. Incidence and course of dementia in people with Down's syndrome: findings from a population-based study. Journal of Intellectual Disability Research 2000;44: 138-146 (Pubitemid 30386552)
26. Janicki MP. Developmental disabilities and Alzheimer's disease. Arlington, TX: The Arc of the United States, 1995.
27. Janicki MP, Dalton A. Prevalence of dementia and impact on intellectual disability services. Mental Retardation 2000;38:277-289
28. Lilienfield S. Galantamine: a novel cholinergic drug with a unique dual mode of action for the treatment of patients with Alzheimer's disease. CNS Drug Reviews 2002;8(2):159-176
29. Loy C, Schneider L. Galantamine for Alzheimer's disease and mild cognitive impairment. Cochrane Database of Systematic Reviews 2006, Issue Issue 1. Art. No.: CD001747. [DOI: DOI: 10.1002/14651858.CD001747.pub3]
30. Maelicke A, Coban T, Storch A, Schrattenholz A, Pereira EF, Albuquerque EX. Allosteric modulation of Torpedo nicotinic acetylcholine receptor ion channel activity by noncompetitive agonists. Journal of Receptor and Signal Transduction Research 1997;17:11-28. (Pubitemid 27057350)
31. Mohan M, Carpenter PK, Bennett C. Donepezil for dementia in people with Down syndrome. Cochrane Database of Sys- tematic Reviews 2009, Issue 1.[Art. No.: CD007178. DOI: 10.1002/14651858.CD007178.pub2] (Pubitemid 351807281)
32. Mohan M, Bennett C, Carpenter PK. Rivastigmine for dementia in people with Down syndrome. Cochrane Database of Systematic Reviews 2009, Issue 1.[Art. No.: CD007658. DOI: 10.1002/14651858.CD007658]
33. Mohan M, Bennett C, Carpenter PK. Memantine for dementia in people with Down syndrome. Cochrane Database of Systematic Reviews 2009, Issue 1.[Art. No.: CD007657. DOI: 10.1002/14651858.CD007657]
34. Moss MB, Albert MS, Butters N, et al. Differential patterns of memory loss among patients with Alzheimer's disease, Huntington's disease, and alcoholic Korsakoff 's syndrome. Archives of Neurology 1986; 43:239-246 (Pubitemid 16117835)
35. National Collaborating Centre for Mental Health. Dementia: A NICE-SCIE Guideline on Supporting People with Dementia and Their Carers in Health and Social Care (available online: http://www.scie.org.uk/publications/misc/ dementia/dementia-full-guideline.pdf, accessed November 2008). Leicester, UK: The British Psychological Society and Gaskell, 2006.
36. National Institute Health and Clinical Excellence. Donepezil, galantamine, rivastigmine (review) and memantine for the treatment of Alzheimer's disease: Guidance type: Technology appraisal. Accessible online: http: //www.nice.org.uk/guidance/index.jsp?action=download&o=36557 (last accessedMay 2008). Vol. TA111, London: NICE, Date issued: September 2007.
37. Nihira K, Foster R, Shallhaas M, Leland H. . Vol.1974 Revision. Washington, DC: American Association on Mental Deficiency. AAMD Adaptive Behaviour Scale. Revised. Washington, DC: American Association on Mental Deficiency, 1974.
38. Prasher VP. Age-specific prevalence, thyroid dysfunction and depressive symptomatology in adults with Down syndrome and dementia. International Journal of Geriatric Psychiatry 1995;10:25-31.
39. Prasher VP, Percy M. Developmental disabilities in Ontario. Ohio: Front Porch Publishing, 1999.
40. Prasher V, Farooq A, Holder R. The Adaptive Behaviour Dementia Questionnaire (ABDQ): screening questionnaire for dementia in Alzheimer's disease in adults with Down syndrome. Research in Developmental Disabilities 2004;25(4):385-397 (Pubitemid 38749097)
41. Prasher V. Review of donepezil, rivastigmine, galantamine and memantine for the treatment of dementia in Alzheimer's disease in adults with Downs syndrome: implications for the intellectual disability population. International Journal of Geriatrics Psychiatry 2004;19: 509-515 (Pubitemid 38877997)
42. Sekijima Y, Ikeda S, Tokuda T, Satoh S, Hidaka H, Hidaka E, et al. Prevalence of dementia of Alzheimer type and apolipoprotein E phenotypes in aged patients with Down's syndrome. European Neurology 1998;39:331-335 (Pubitemid 28230404)
43. Stanton LR, Coetzee RH. Downs syndrome and dementia. Advances in Psychiatric Treatment 2004;10:50-58
44. Sweeney JE, Hohmann CF, Moran TH, Coyle JT. A long-acting cholinesterase inhibitor reverses spatial memory deficits in mice. Pharmacology Biochemistry and Behavior 1988;31(1):147-157
45. Teller JK, Russo C, DeBusk LM, Angelini G, Zaccheo D, Dagna-Bricarelli F, et al. Presence of soluble amyloid B - Peptide precedes amyloid plaque formation in Down's syndrome. Nature Medicine 1996;2:93-95 (Pubitemid 26028078)
46. Visser FE, Aldenkamp AP, van Huffelen AC, Kuilman M, Overweg J, & van Wijk J Visser FE, et al. Prospective study of the prevalence of Alzheimer-type dementia in institutionalized individuals with Downs syndrome. American Journal on Mental Retardation 1997;101:400-412 (Pubitemid 27061358)
47. Wisniewski KE, Wisniewski HM, Wen GY. Occurence of neuropathological changes and dementia of Alzheimer's disease in Down's syndrome. Annals of Neurology 1995;17:278-282
48. Woodruff-Pak DS, Vogel RW 3rd, Wenk GL. Galantamine: effect on nicotinic receptor binding, acetylcholinesterase inhibition, and learning. Proceedings of the National Academy of Sciences of the United States of America 2001;98(4):2089-2094
49. Zigman W, Silverman W, Wisniewsi H. Aging and Alzheimer's disease in Down Syndrome: Clinical and pathological changes in Down Syndrome: Clinical and pathological changes. Mental Retardation & Developmental Disability Research Reviews 1996;2(2):73-79